Endpoint Health
Endpoint Health is a clinical-stage precision immunology company developing an integrated therapeutics, diagnostic, and AI platform to treat immune-mediated diseases, with its lead Antithrombin III program advancing to Phase II trials for sepsis.
- Company typePrivate
- Founded2018
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Endpoint Health does
Endpoint Health is a precision immunology company founded in 2018 and headquartered in Palo Alto, California. The company is developing an integrated platform that combines therapeutics, diagnostic tests, and artificial intelligence to deliver targeted treatments for immune-mediated diseases, with an initial clinical focus on sepsis. Its lead asset is the Antithrombin III program, a therapeutic candidate advancing into Phase II clinical trials, with planned regulatory submissions to the FDA.
The company was co-founded by Jason Springs (CEO), Leonardo Maestri Teixeira (COO), and Diego Rey (CSO), and is venture-backed. To date, Endpoint Health has raised approximately $64 million across funding rounds, including a $52 million Series A in June 2022 led by Mayfield Fund with participation from AME Cloud Ventures, Humboldt Fund, the Global Health Investment Fund, Y Combinator alumni investors, and several other institutional investors. The company went through the Y Combinator accelerator in 2019.
Endpoint Health is a pre-commercial, clinical-stage biotechnology company. It has no approved products, no disclosed revenue, and no commercial customers. Its business model is built around developing and ultimately commercializing precision immunology therapeutics, with an integrated companion diagnostic and AI-based patient stratification component. Revenue generation would be dependent on successful clinical trial outcomes, regulatory approval, and future commercialization of its therapeutic pipeline.
Endpoint Health firmographics
Firmographics- Name
- Endpoint Health
- Legal name
- Endpoint Health, Inc.
- Website
- https://endpointhealth.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Endpoint Health is a clinical-stage precision immunology company developing an integrated therapeutics, diagnostic, and AI platform to treat immune-mediated diseases, with its lead Antithrombin III program advancing to Phase II trials for sepsis.
- Ownership category
- akta.pro rank
Endpoint Health industry classification
Industry- Product category
- Precision Immunology Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medical and Diagnostic Laboratories (62151)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Imaging Core Labs & Clinical Endpoint Adjudication (HLAGAEAH)
- akta.pro secondary industry
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
Keywords
Where Endpoint Health is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Endpoint Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Therapeutic Product Revenue: Revenue derived from developing and commercializing precision immunology therapeutics. The company is in clinical development stage with Antithrombin III program advancing to Phase II trials for sepsis treatment.
Endpoint Health product offering
Product offeringCore offering
Endpoint Health is a clinical-stage therapeutics company developing precision immunology treatments for immune-mediated diseases. Its lead program is Antithrombin III, a therapeutic candidate for sepsis that is progressing to a Phase II clinical trial with planned FDA regulatory submissions. The company combines therapeutics, diagnostic tests, and artificial intelligence within a single platform to enable targeted treatment of conditions such as sepsis.
Product overview
Endpoint Health operates as a therapeutics company developing precision therapies for immune-mediated diseases. The company's portfolio includes the Antithrombin III Program, a therapeutic candidate for sepsis undergoing Phase II clinical development. The offerings combine therapeutics, diagnostic tests, and AI technologies to enable precision immunology approaches.
Differentiator
Problem solved
Functional benefit
Products and services
- Antithrombin III Program
Companies that use Endpoint Health
Customer profileSegments1 record
Ideal customer profiles1 record
Endpoint Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Endpoint Health partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights5 records
Endpoint Health competitors and assessment
Company assessmentBroad incumbents
- Roche: Roche operates across diagnostics, immunology therapeutics, and AI-driven clinical decision support — a broad incumbent whose portfolio most closely mirrors Endpoint Health's stated integrated therapeutics–diagnostics–AI strategy at scale.
- Regeneron Pharmaceuticals: Regeneron is a leading immunology therapeutics developer (Dupixent, IL-4Rα franchise) with a track record of combining biologics with genetic/diagnostic patient selection — a large incumbent demonstrating the precision immunology commercial model Endpoint Health aspires to.
- Grifols: Grifols markets Thrombate III (Antithrombin III) for hereditary antithrombin deficiency and has hospital-channel reach in critical care — an established competitor whose antithrombin franchise could overlap with a commercialized Endpoint Health product.
- Takeda Pharmaceutical: Takeda markets ATryn, a recombinant antithrombin product, and has deep critical-care commercial infrastructure — a broad incumbent comparable on the antithrombin therapeutic modality and ICU channel access.
- Asahi Kasei Pharma: Asahi Kasei markets an antithrombin III concentrate and is a major global plasma-derived therapeutics manufacturer — a broad incumbent with potential overlap in the antithrombin sepsis positioning.
- bioMérieux: bioMérieux (including BioFire Diagnostics) is a global leader in clinical microbiology and sepsis diagnostics — an established incumbent in the diagnostic-and-AI sepsis workflow that Endpoint Health's diagnostic components would compete against.
Direct peers
- Cytovale: Cytovale markets IntelliSep, a rapid cellular biomarker diagnostic that aids early sepsis identification in the ER — a direct analog to Endpoint Health's diagnostic-test-driven approach to sepsis decision-making.
- Inflammatix: Inflammatix develops AI/ML-based host-response diagnostics for acute infections and sepsis — directly comparable to Endpoint Health's integration of diagnostics and AI for immune-mediated disease management.
- Inotrem: Inotrem is a French clinical-stage biotech developing a TREM-1 inhibitor (nangibotide) for septic shock — a precision immunology approach to sepsis therapeutics that competes head-to-head with Endpoint Health's positioning.
Emerging players
- Prenosis: Prenosis applies AI-driven biomarker analytics to immune-mediated disease diagnostics (e.g., Sepsis ImmunoScore) — closely aligned with Endpoint Health's precision immunology platform combining diagnostics, AI, and clinical decision support.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Endpoint Health social profiles
Digital presenceEndpoint Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Endpoint Health leadership team
Management profileNumber of profiles
Profiles3 records
Endpoint Health funding detail
Funding detailFunding overview
Funding rounds5 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Endpoint Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Endpoint Health
What does Endpoint Health do?
Endpoint Health is a clinical-stage therapeutics company developing precision immunology treatments for immune-mediated diseases. Its lead program is Antithrombin III, a therapeutic candidate for sepsis that is progressing to a Phase II clinical trial with planned FDA regulatory submissions. The company combines therapeutics, diagnostic tests, and artificial intelligence within a single platform to enable targeted treatment of conditions such as sepsis.
Is Endpoint Health a public or private company?
Endpoint Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Endpoint Health founded?
Endpoint Health was founded in 2018. It employs 11 to 50 people.
Where is Endpoint Health based?
Endpoint Health is headquartered in Palo Alto, United States, in the North America region.
How does Endpoint Health make money?
One revenue line is on record: therapeutic Product Revenue.
Who are Endpoint Health's main competitors?
Broad incumbents on record are Roche, Regeneron Pharmaceuticals, Grifols, Takeda Pharmaceutical, Asahi Kasei Pharma and bioMérieux. Direct peers are Cytovale, Inflammatix and Inotrem. Prenosis is listed as an emerging player.
Does Endpoint Health have an API?
No public API is recorded for Endpoint Health.
What industry is Endpoint Health in?
Endpoint Health's product category is Precision Immunology Therapeutics. Its primary akta.pro industry code is HLAGAEAH, Imaging Core Labs & Clinical Endpoint Adjudication, with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 325412 and its SIC code is 2834.